Stifel CEO Ron Kruszewski discusses deregulation, economic growth, his expectations for the Federal Reserve handling of rates ...

Fintel reports that on January 22, 2025, Stifel initiated coverage of Edgewise Therapeutics (NasdaqGS:EWTX) with a Hold ...

Stifel has initiated coverage of Cytokinetics (CYTK) with a buy rating, citing its drug aficamten, valuation and upcoming ...

Stifel initiated coverage of Cytokinetics (CYTK) with a Buy rating and $80 price target Cytokinetics “is an out-of-favor stock” following the ...

Stifel initiated coverage of Edgewise Therapeutics (EWTX) with a Hold rating and $30 price target The firm says that while Edgewise has “very ...